Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

BACKGROUND: Interest in patient-reported outcomes (PROs) as part of benefit–risk assessment for new drug approvals is increasing. Lefamulin is the first intravenous (IV) and oral pleuromutilin antibiotic for treatment of adults with community-acquired bacterial pneumonia (CABP). Assessment of health...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodise, Thomas P, Colman, Sam, Alexander, Elizabeth, Stein, Daniel S, Fitts, David, Goldberg, Lisa, Schranz, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314585/
https://www.ncbi.nlm.nih.gov/pubmed/32617376
http://dx.doi.org/10.1093/ofid/ofaa209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314585/
https://www.ncbi.nlm.nih.gov/pubmed/32617376
http://dx.doi.org/10.1093/ofid/ofaa209

Ejemplares similares